Mitesh Patel is a Cardiovascular Diseases physician. ClinicalTrials.gov lists 22 registered studies with this person as an investigator.
Data verified 13 Nov 2026
Overview
Updated 13 Nov 2026
Mitesh Patel, D.O, is profiled from the public federal record. It also documents an investigator role on 22 registered clinical trials, industry payments reported by 3 companies.
- Top research focus: Cardiovascular Diseases
- 22 registered trials on ClinicalTrials.gov
- Open Payments reporting from 3 companies
Generated from the cited public record · current as of 13 Nov 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 13 Nov 2026
Listed as an investigator on 22 registered studies on ClinicalTrials.gov. The most recent:
- Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
Sponsor: Mitesh Patel
- Intermittent Fasting Adherence and Self Tracking
Sponsor: University of Pennsylvania
Industry payments
Updated 13 Nov 2026
3 companies reported payments to CMS in program years 2022–2024. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year20241 payment
- Janssen Pharmaceuticals, IncProgram year20221 payment
- Boston Scientific CorporationProgram year20221 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
74.4%Beta blocker21.1%Metoprolol Tartrate37%Carvedilol29%Metoprolol Succinate29%Sotalol5%Part D<11 patientsStatin11.2%Atorvastatin Calcium70%Rosuvastatin Calcium30%Part D≥74 patients+ 13 more classes in this area
Blood & clotting
22.1%Factor Xa inhibitor14.5%Eliquis82%Xarelto18%Part D≥87 patientsP2Y12 inhibitor4.3%Clopidogrel100%Part D≥40 patients+ 1 more class in this area
Metabolism & gastrointestinal
3.5%SGLT2 inhibitor2.3%Jardiance100%Part D≥19 patientsPotassium supplement1.2%Potassium Chloride100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
None on file yet. We only list publications we can confidently match to this person. Why? →
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Martin Leon, MD
Columbia University Irving Medical Center
Gregg Fonarow, MD
Ronald Reagan UCLA Medical Center